Ono Pharmaceutical Co. Ltd.

OPHLY | OTC

Price Alert Chart Builder DCF Calculator

$5.35

+$0.20 (+3.88%)

Sep 22, 2026, 2:13 PM ET · Market open

Overview Rating Statistics Financials Earnings Ownership Dividends Profile

+3.88%

(1D)

Rating

Updated: Sep 17, 2026

68.5

Fundamentals Excellent

Market Sentiment Neutral

Moat Narrow

Full Analysis

Key Statistics

Market Data

Market Cap $7.54B

1D Range

5.24 5.36

52W Range

3.71 5.75

Valuation (TTM)

PE 14.39

PB 1.37

EV/EBITDA 7.09

Valuation (NTM)

Forward PE 15.62

Forward PEG -1.25

Price Target N/A

Cash Flow

FCF Yield 11.5%

SBC Adj. FCF Yield 11.5%

SBC Impact N/A

Margins

Gross Margin 73.6%

Operating Margin 22.1%

FCF Margin 25.8%

Growth (CAGR)

Revenue 3Y | 5Y 3.7% | 9.8%

Dil EPS 3Y | 5Y 17.6% | 26.0%

FCF 3Y | 5Y 10.3% | 22.8%

Returns

ROA 7.0%

ROE 9.1%

ROIC 8.5%

Financial Health

Net Cash

¥110.65B ($680.84M)

Current Ratio 3.28

Interest Coverage 31.37

Dividends

Div Yield 3.30%

Payout Ratio 0.3%

FCF Payout Ratio 28.5%

All Key Statistics

Loading financial charts...

Profile

A detailed description of the company is not yet available.

Sector n/a

Industry n/a

Employees n/a

IPO Date n/a

Website n/a

Fiscal Year n/a

Full Company Profile

Latest News

21 days ago · businesswire.com

Ono Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological Diseases

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced that it has entered into a drug discovery partnership agreement with Aitia, Inc. (Headquarters: Cambridge, Massachusetts, USA; CEO: Colin Hill; “Aitia”). Under the terms of the agreement, Aitia will utilize its REFS™ technology to build Gemini Digital Twins (GDTs) of neurological diseases and identify new therapeutic targets and bio.

Earnings

Next Earnings

Nov 2, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞